<span item_type="fundamental" item_id="0ca96fba0d5301a2af230bc7b7f493cc" counter_id="ST/US/UG" env="prod"></span><span item_type="announcement" item_id="646092539485225345" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 2.872 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD 0.18.</p><p>EBIT: As of FY2026 Q1, the actual value is USD 642.45 K.</p><p></p><h4>Net Sales</h4><p>United-Guardian, Inc.’s net sales increased to $2,872,222 in the first quarter of 2026, up from $2,481,127 in the first quarter of 2025, representing a 15.7% increase year-over-year. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span></p><h4>Net Income</h4><p>Net income for the first quarter of 2026 rose to $818,902, compared to $560,895 in the same period of 2025, marking a 46.0% increase. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span></p><h4>Segment Revenue Performance</h4><p>Pharmaceutical sales increased by 24% in the first quarter of 2026, primarily due to higher demand for Renacidin®. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span> Sales of cosmetic ingredients grew by 21%, mainly driven by a 45% increase in purchases from Ashland Specialty Ingredients (ASI). <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span></p><h4>Operational Costs and Income</h4><ul><li><strong>Cost of Sales:</strong> Increased to $1,447,789 in Q1 2026 from $1,123,076 in Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span></li><li><strong>Operating Expenses:</strong> Rose to $666,963 in Q1 2026 from $632,735 in Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span></li><li><strong>Research and Development:</strong> Slightly increased to $115,021 in Q1 2026 from $114,394 in Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span></li><li><strong>Total Costs and Expenses:</strong> Amounted to $2,229,773 in Q1 2026, up from $1,870,205 in Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span></li><li><strong>Income from Operations:</strong> Increased to $642,449 in Q1 2026 from $610,922 in Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span></li></ul><h4>Other Income</h4><p>Total other income significantly increased to $390,689 in Q1 2026 from $97,037 in Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span> This increase was substantially due to $303,133 in settlement income recognized from the contract manufacturer of Renacidin. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span> Investment income decreased to $69,814 from $84,687, while net gain on marketable securities increased to $17,742 from $12,350. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span></p><h4>Income Before Taxes and Provision for Income Taxes</h4><p>Income before provision for income taxes was $1,033,138 in Q1 2026, up from $707,959 in Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span> The provision for income taxes was $214,236 in Q1 2026, compared to $147,064 in Q1 2025. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span></p><h4>Outlook</h4><p>United-Guardian, Inc. is optimistic about continued sales increases in 2026. This outlook is driven by Ashland Specialty Ingredients resuming regular purchasing patterns, new distribution agreements, and an increased focus on expanding “natural” product lines. Additionally, ongoing efforts to boost outreach and market penetration for Renacidin are expected to contribute to growth. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/101295/000117184326003193/exh_991.htm"></span></p>

United-Guardian | 8-K: FY2026 Q1 Revenue: USD 2.872 M